Table 3.
Classification | Biomarkers | Expression | Species | Type of biological fluid | AUROC | Clinical significance | Refs | |
---|---|---|---|---|---|---|---|---|
m/lEvs | AnnexinV+EpCAM+ASPGR1+CD133+taMPs | ↑ | Human | serum | 0.7439 | Diagnosis of HCC/CCA from LC | (225) | |
EpCAM+AnnexinV +ASGPR1+taMPs | ↑ | Human | serum | 0.7322 | Diagnosis of HCC/CCA from LC | (225) | ||
Total m/lEVs of peripheral blood | ↑ | Human | serum | 0.83 | Diagnosis of E-HCC from LC (TNM stage I) | (226) | ||
sEVs | microRNA | miR-148a | ↑ | Human | serum | 0.871 | Diagnosis of HCC from NC Diagnosis of E-HCC from LC | (227) |
0.860 | ||||||||
miR-122 | ↑ | Human | serum | 0.990 | Diagnosis of HCC from NC Diagnosis of E-HCC from LC | (227) | ||
0.795 | ||||||||
miR-1246 | ↑ | Human | serum | 0.825 | Diagnosis of HCC from NC Diagnosis of E-HCC from LC | (227) | ||
0.761 | ||||||||
miR-638 | ↑ | Human | serum | —— | Associated with tumor recurrence, As a prognostic marker | (228) | ||
miR-125b | ↑ | Human | serum | 0.739 | Prediction of recurrence and survival | (229) | ||
miR-93 | ↑ | Human | serum | 0.825 | The prognosis and diagnosis of HCC | (147) | ||
miR-665 | ↑ | Human, | serum | —— | Diagnosis and prognosis of HCC | (230) | ||
Mice | ||||||||
miR-92b | ↑ | Human, | serum | 0.702 | Prediction of E-HCC relapse after LDLT | (231) | ||
Rats | ||||||||
miR-21 | ↑ | Human | serum | —— | Detection of E-HCC, Prognostic marker | (232) | ||
miR-718 | ↑ | Human | serum | —— | Prediction of HCC relapse after LDLT | (233) | ||
miR-21-5p | ↑ | Human | serum | 0.71 | Diagnosis of HCC from LC | (234) | ||
miR-21, miR-10b | ↑ | Human, | serum | —— | Prognostic markers of E-HCC | (235) | ||
Mice | ||||||||
miR-18a, miR221, miR-222, miR224 | ↑ | Human | serum | —— | Diagnosis of HCC from LC/CHB | (223) | ||
miR-101, miR106b, miR-122, miR-195 | ↑ | Human | serum | —— | Diagnosis of HCC from CHB | (223) | ||
miR-122, miR148a, miR-1246 | ↑ | Human | serum | —— | Diagnosis of HCC from LC | (227) | ||
miRNA-519d, miR-595, miR-939 | ↑ | Human | serum | —— | Diagnosis of HCC from LC | (222) | ||
miR-10b-5p, miR-221-3p, miR-223-3p, miR-21-5p | ↑ | Human | plasma | 0.86 | Diagnosis of HCC from CH or LC | (234) | ||
lncRNA | lncRNA-HEIH | ↑ | Human | serum | —— | Diagnosis of HCV-associated HCC from CHC | (236) | |
LINC02394 | ↑ | Human | serum | 0.719 | Diagnosis of HCC from CHB | (237) | ||
LINC00635 | ↑ | Human | serum | 0.750 | Diagnosis of HCC from CHB | (237) | ||
LINC00161 | ↑ | Human | serum | 0.794 | Prediction of HCC growth and metastasis | (238) | ||
IncRNA-ATB | ↑ | Human | serum | —— | The prognosis of HCC | (239) | ||
Lnc85 | ↑ | Human | plasma | 0.869 | Diagnosis of AFP-negative HCC from healthy controls and LC | (163) | ||
SENP3-EIF4A1 | ↑ | Human,Mice | plasma | 0.8028 | The diagnosis of HCC | (160) | ||
circRNA | circFBLIM1 | ↑ | Human,Mice | serum | —— | The therapeutic target of HCC | (149) | |
circ-0051443 | ↑ | Human,Mice | plasma | 0.8089 | The diagnosis and therapeutic target of HCC | (161) | ||
circRNA-100338 | ↑ | Human,Mice | serum | —— | The diagnosis and therapeutic target of HCC | (240) | ||
circUHRF1 | ↑ | Human,Mice | plasma | —— | The therapeutic target of HCC | (169) | ||
circ-DB | ↑ | Human,Mice | adipocyte | —— | The prognosis of HCC | (202) | ||
proteins | LAPTM4B-35 | ↑ | Human | serum | —— | Prediction of recurrence and diagnosis of HCC | (241) | |
SMAD3 | ↑ | Human,Mice | peripheral blood | 0.70 | The diagnosis of HCC | (242) | ||
RAB5A | ↑ | Human | serum | —— | The diagnosis and therapeutic target of HCC | (243) | ||
ENO1 | ↑ | Human,Mice | serum | —— | The prognosis of HCC | (244) | ||
Other combinations | miR-122, miR-148a, AFP | ↑ | Human | serum | 0.931 | Diagnosis of HCC from LC | (227) | |
SMAD3+ATP | ↑ | Human,Mice | peripheral blood | 0.90 | The diagnosis of HCC | (242) | ||
lncRNA-RP11-513I15.6, miR-1262/RAB11A | ↑ | Human | serum | —— | Diagnosis of E-HCC from CHB | (245) | ||
miRNA-21, lncRNA-ATB | ↑ | Human | serum | —— | The prognosis of HCC, overall survival | (239) | ||
ENSG00000258332.1, LINC00635, AFP | ↑ | Human | serum | 0.894 | The diagnosis and prognosis of HCC | (237) | ||
AFP、ENST00000248932.1, ENST00000440688.1, ENST00000457302.2 | ↑ | Human | plasma | 0.905 0.879 |
Predict the probability of HCC in the cancer‐free groups Predict the probability of HCC in the CH groups |
(246) | ||
Total EVs | Total EV | ↑ | Human | serum | 0.83 | Detection of HCC | (225) | |
AFP, GPC3, ALB, APOH, FABP1, FGB, FGG, AHSG, RBP4, TF | ↑ | Human | plasma | 0.93 | Diagnosis of E-HCC from LC | (247) | ||
LINC00853 | ↑ | Human | serum | 0.956 | Diagnosis of E-HCC from CH、LC | (248) |